Biotech & Life Sciences

One video claimed "100% patient improvement in Phase 2 trials." Another said one dose "could do what years of antidepressants could not." Both were paid ads.

Thirty years in HIV. Thirteen at ViiV. The injectable franchise she built is now facing Gilead's twice-yearly lenacapavir — and the scientist who built it is leaving.

Biogen paid $5.6B upfront—but the real bet is whether it can build a market for SYFOVRE, the first approved GA drug, when less than 10 percent of diagnosed patients currently receive any treatment.

One patient got 70.8% worse. That single outlier turned a 22.9% signal into noise — and buried what PepGen needed its lowest-dose cohort to show.

Lilly paid $6.3B for a sleep drug that targets the brain master switch for wakefulness. The CEO who built it had been in the job for three months.

The IND filing sits on someone's desk at Alltrna. The CEO who fought for it isn't there anymore.

An oral eczema drug with JAK-inhibitor-like efficacy and biologic-like safety — without the injections. That is what Enveda says the data shows. The specific numbers are not yet public.

Chinese academic labs are now the most contested real estate in drug development. US investors need scientists to publish; Chinese investors need them to stay quiet — and both sides are racing to get there first.

"One of them is going to end up on the front page of The New York Times with a disaster story," Jimini's CEO told investors. The FDA has cleared 1,200+ AI medical devices but zero generative AI tools for mental health. Here's why that gap matters.

Ancestry, not natural selection, set the boundaries of what proteins could ever be. AI tools trained on life's existing catalog may be exploring a narrow path, not the full landscape.

Engineered bacteria that hunt superbugs without replicating — Oxford just published the evidence.